Limits...
Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy.

Fallowfield L, Gagnon D, Zagari M, Cella D, Bresnahan B, Littlewood TJ, McNulty P, Gorzegno G, Freund M, Epoetin Alfa Study Gro - Br. J. Cancer (2002)

Bottom Line: Cancer-related anaemia is associated with a wide spectrum of symptoms that can negatively affect quality of life.The a priori-planned multiple linear regression analysis, which accounted for the effects of disease progression and several other possibly confounding variables on quality of life, showed a significant advantage for epoetin alfa over placebo for the five scales (all, P<0.05), and confirmed the results of the univariate analysis.For cancer-specific measures, significant correlations were demonstrated between baseline haemoglobin and quality of life (r, range: 0.14-0.26, all P<0.05) and between change in haemoglobin and change in quality of life (r, range: 0.26-0.34, all P<0.01).

View Article: PubMed Central - PubMed

Affiliation: Cancer Research UK Psychosocial Oncology Group, Brighton and Sussex Medical School, University of Sussex, Brighton, BN1 9QG, UK. l.fallowfield@biols.susx.ac.uk

Show MeSH

Related in: MedlinePlus

Visual graphic demonstrating the relationship between Hb and QoL over time by showing biweekly Hb levels and CLAS Energy levels from univariate analysis (Littlewood et al, 2001).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2376290&req=5

fig7: Visual graphic demonstrating the relationship between Hb and QoL over time by showing biweekly Hb levels and CLAS Energy levels from univariate analysis (Littlewood et al, 2001).

Mentions: Correlation analyses were performed to examine the relationship between Hb level and QoL (Table 7Table 7Correlation between haemoglobin level and QoL scores). Positive cross-sectional correlations were found for every scale except the SF-36 MCS scale. Slightly stronger longitudinal correlations were found using all seven primary QoL scales; all P values were significant (range, P<0.01 to P=0.03). Figure 7Figure 7


Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy.

Fallowfield L, Gagnon D, Zagari M, Cella D, Bresnahan B, Littlewood TJ, McNulty P, Gorzegno G, Freund M, Epoetin Alfa Study Gro - Br. J. Cancer (2002)

Visual graphic demonstrating the relationship between Hb and QoL over time by showing biweekly Hb levels and CLAS Energy levels from univariate analysis (Littlewood et al, 2001).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2376290&req=5

fig7: Visual graphic demonstrating the relationship between Hb and QoL over time by showing biweekly Hb levels and CLAS Energy levels from univariate analysis (Littlewood et al, 2001).
Mentions: Correlation analyses were performed to examine the relationship between Hb level and QoL (Table 7Table 7Correlation between haemoglobin level and QoL scores). Positive cross-sectional correlations were found for every scale except the SF-36 MCS scale. Slightly stronger longitudinal correlations were found using all seven primary QoL scales; all P values were significant (range, P<0.01 to P=0.03). Figure 7Figure 7

Bottom Line: Cancer-related anaemia is associated with a wide spectrum of symptoms that can negatively affect quality of life.The a priori-planned multiple linear regression analysis, which accounted for the effects of disease progression and several other possibly confounding variables on quality of life, showed a significant advantage for epoetin alfa over placebo for the five scales (all, P<0.05), and confirmed the results of the univariate analysis.For cancer-specific measures, significant correlations were demonstrated between baseline haemoglobin and quality of life (r, range: 0.14-0.26, all P<0.05) and between change in haemoglobin and change in quality of life (r, range: 0.26-0.34, all P<0.01).

View Article: PubMed Central - PubMed

Affiliation: Cancer Research UK Psychosocial Oncology Group, Brighton and Sussex Medical School, University of Sussex, Brighton, BN1 9QG, UK. l.fallowfield@biols.susx.ac.uk

Show MeSH
Related in: MedlinePlus